In a 72-hour MTT assay, GSK461364 gave GI50 values of 10 ± 1.5 nM in SK-N-AS and 13 ± 4 nM in IMR32 neuroblastoma cells. Sensitivity varied across the six-cell-line panel, with SH-SY5Y less sensitive than these two models. The viability endpoint alone does not establish apoptosis. [2]
Cellular responses depend on context. In HCT116 cells treated with 20 nM GSK461364 for 8 h, centrosome-separation failure occurred in 16% of p53-competent mitotic cells and >60% of p53-null cells. This is evidence for a p53-associated difference in this isogenic model. [3]
PLK1 kinase activity under high-ATP conditions
Biochemical assay · Recombinant human wild-type PLK1 kinase domain, residues 33–345 [1]
GSK461364 inhibited peptide phosphorylation with an IC50 of 2.5 nM at 10 mM ATP. Table 4 reports n = 1; this is an assay IC50, not a binding constant or treatment dose.
Literature-Reported Treatment Conditions
- Treatment concentration
- 11 concentrations from 20 µM to 0.1 nM; duplicate wells per concentration
- Exposure duration
- 15 min pre-binding; 30 min kinase reaction at 22°C
- Method
- TR-FRET peptide-phosphorylation assay; four-parameter IC50 fit
- Vehicle
- DMSO; test compounds added as 100-fold concentrated DMSO solutions
- Reported limits
- Table 4 gives n = 1 without uncertainty for GSK461364. Normalization control definitions are not stated in Section 2.3.
Methods and source locations
Compound reported in the paper: GSK461364
Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.
Section 2.3; Table 4, GSK461364 row; Section 3.2
Inhibition of PLK1-dependent substrate phosphorylation at 10 mM ATP: TR-FRET; duplicate concentrations; n = 1 as printed in Table 4 is distinct from technical duplicate wells. — Section 2.3; Table 4, GSK461364 row
GSK461364 binding in a PLK1 co-crystal
Biochemical assay · Human PLK1 kinase domain residues 18–340 with K225D/K226A surface mutations; PDB 9r1y [1]
The co-crystal places GSK461364 in the ATP-binding pocket, with an imidazole nitrogen hydrogen-bonded to the Cys133 backbone amide. The structure uses a surface-mutated kinase domain.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 mM ligand for co-crystallization
- Exposure duration
- 1–2 h ligand preincubation at 277 K; crystal growth at 293 K
- Method
- X-ray co-crystallography of the K225D/K226A kinase domain
- Vehicle
- Ligand stock in DMSO
- Reported limits
- No unmodified full-length PLK1–GSK461364 co-crystal comparison is reported here; no new selectivity panel is inferred.
Methods and source locations
Compound reported in the paper: GSK461364
Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.
Sections 2.2, 2.4, 3.1 and 3.2.3; Figure 1d; Figure 6; Tables 2–3, GSK461364 column
Diffraction resolution for PLK1 K225D/K226A:GSK461364: X-ray diffraction; Table 2 range 42.43–2.60 Å. — Table 2, PLK1 K225D/K226A:GSK461364 column; Figure 6
GSK461364 response in a neuroblastoma viability panel
Cell-based study · Human SK-N-AS, SH-SY5Y, SH-EP, IMR32, Kelly and SK-N-BE neuroblastoma cells, spanning MYCN single-copy/amplified and TP53 wild-type/mutant backgrounds [2]
Sensitivity varied across this 72-hour MTT panel. Exact Figure 1B GI50 labels are 10 ± 1.5 nM for SK-N-AS and 13 ± 4 nM for IMR32. SH-SY5Y is less sensitive by the higher bar in Figure 1A. The viability endpoint does not alone establish cell death or universal biomarker independence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01–1000 nM
- Exposure duration
- 72 h
- Method
- MTT assay, relative to solvent-treated cultures
- Vehicle
- Matched DMSO carrier control
- Reported limits
- Exact number of biological experiments for these displayed fits is not separately given; general Methods state at least three independent experiments in triplicate. ± follows the figure labels; Statistics identifies error bars as SD.
Methods and source locations
Compound reported in the paper: GSK461364
Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.
Results first subsection; Figure 1A–B/caption; Methods: Compound, Cell assays, Statistics
MTT-based viability inhibition in SK-N-AS after 72 h: Exact annotation in Figure 1B; not digitized from curve. General Statistics: SD. — Figure 1B, SK-N-AS GI50 annotation; Figure 1 caption; Statistics
MTT-based viability inhibition in IMR32 after 72 h: Exact annotation in Figure 1B; not digitized from curve. General Statistics: SD. — Figure 1B, IMR-32 GI50 annotation; Figure 1 caption; Statistics
Relative MTT GI50 across the neuroblastoma panel: Visual comparison of original Figure 1A; no exact bar-derived value reported. The Results all-lines <20 nM statement conflicts with the SH-SY5Y bar and is not adopted. — Figure 1A and Results first subsection
p53-dependent centrosome response to PLK1 inhibition
Cell-based study · Parental HCT116 p53+/+ and isogenic p53−/− human colorectal carcinoma cells [3]
After 20 nM GSK461364 for 8 h, centrosome-separation failure was more frequent in p53-null cells. Untreated cells of both genotypes showed little failure. This is a model-specific response, not a universal p53 sensitivity rule.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 nM
- Exposure duration
- 8 h
- Method
- γ-Tubulin immunofluorescence; mitotic cells identified by DAPI; >100 cells per condition, scored by two individuals
- Vehicle
- DMSO control in caption; plotted controls labeled untreated
- Reported limits
- DMSO concentration not specified for Figure 7B. Representative of two independent experiments; caption calls error bars the standard deviation of the mean.
Methods and source locations
Compound reported in the paper: GSK461364
Evidence for the named research compound in this reported material and model; no Adooq lot, formulation equivalence or clinical efficacy validation.
Results: p53 protects cells from PLK1 inhibition by maintaining centrosome separation; Figure 7B/caption; Cell culture; Antibodies and reagent; Immunofluorescence
Mitotic cells failing centrosome separation after GSK461364: Values are reported in Results, corroborated qualitatively by viewed Figure 7B; no exact graph-derived decimals. — Results, paragraph beginning PLK1 is a major upstream component; Figure 7B/caption